New trial
Regorafenib and Yttrium-90 Radioembolization for Unresectable HCC
- Trial ID
- NCT06902246 on ClinicalTrials.gov
- Cancer type
- Hepatocellular Carcinoma (Liver)
- Published in
- New in Oncology - May 21, 2025
A trial is underway at Miami to assess the impact of combining Regorafenib with Y-90 trans-arterial radioembolization in patients with unresectable hepatocellular carcinoma over an estimated 37-month period.
More in liver and bile duct cancer
-
New trial · Sep 17, 2026 · NCT07793253
Phase 2 daraxonrasib pan-RAS(ON) tri-complex inhibitor targets KRAS-mutant biliary tract cancer. -
Trial result · Sep 10, 2026 · NCT05301842
STRIDE (durvalumab + tremelimumab) + VEGFR/FGFR TKI lenvatinib + TACE extends PFS in embolisation-eligible HCC -
New trial · Sep 10, 2026 · NCT07780838
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade -
New trial · Sep 3, 2026 · NCT07766187
Phase 2 durvalumab PD-L1 inhibitor plus histotripsy non-thermal focused ultrasound ablation in iCCA -
New trial · Aug 27, 2026 · NCT07723534
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC